Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
Iterum Therapeutics (Nasdaq: ITRM), a pharmaceutical company specializing in next-generation oral and IV antibiotics for multi-drug resistant pathogens, has scheduled its first quarter 2025 financial results release for May 13, 2025, before U.S. markets open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss financial results and provide a business update.
Investors can access the call via phone at 833-470-1428 (domestic) or 404-975-4839 (international) using Access Code 371859. A pre-registration link is available, and an audio webcast will be accessible in the Investors section of Iterum's website after the call.
Iterum Therapeutics (Nasdaq: ITRM), un'azienda farmaceutica specializzata in antibiotici orali e endovenosi di nuova generazione contro patogeni multi-resistenti, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 13 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call alle 8:30 a.m. ET dello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento sul business.
Gli investitori potranno partecipare alla chiamata telefonando al numero 833-470-1428 (nazionale) o 404-975-4839 (internazionale) utilizzando il codice di accesso 371859. È disponibile un link per la preregistrazione e, dopo la chiamata, sarà possibile ascoltare la trasmissione audio nella sezione Investitori del sito web di Iterum.
Iterum Therapeutics (Nasdaq: ITRM), una compañía farmacéutica especializada en antibióticos orales e intravenosos de próxima generación para patógenos multirresistentes, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el 13 de mayo de 2025, antes de la apertura de los mercados estadounidenses. La empresa realizará una llamada conferencia a las 8:30 a.m. ET el mismo día para analizar los resultados financieros y ofrecer una actualización del negocio.
Los inversores podrán acceder a la llamada telefónica marcando el 833-470-1428 (nacional) o 404-975-4839 (internacional) con el código de acceso 371859. Hay un enlace para preinscribirse y, tras la llamada, estará disponible una transmisión de audio en la sección de Inversores del sitio web de Iterum.
Iterum Therapeutics(나스닥: ITRM)은 다제내성 병원체를 대상으로 하는 차세대 경구 및 정맥 주사 항생제 전문 제약회사로, 2025년 1분기 재무 실적을 2025년 5월 13일 미국 시장 개장 전 발표할 예정입니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 재무 실적과 사업 현황을 논의하는 컨퍼런스 콜을 진행합니다.
투자자들은 국내 전화 833-470-1428 또는 국제 전화 404-975-4839에 접속 코드 371859를 사용하여 콜에 참여할 수 있습니다. 사전 등록 링크가 제공되며, 콜 종료 후 Iterum 웹사이트 투자자 섹션에서 오디오 웹캐스트를 들을 수 있습니다.
Iterum Therapeutics (Nasdaq : ITRM), une société pharmaceutique spécialisée dans les antibiotiques oraux et intraveineux de nouvelle génération contre les pathogènes multirésistants, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le 13 mai 2025, avant l'ouverture des marchés américains. La société tiendra une conférence téléphonique à 8h30 ET le même jour afin de discuter des résultats financiers et de fournir une mise à jour sur ses activités.
Les investisseurs peuvent accéder à la conférence téléphonique par téléphone au 833-470-1428 (national) ou 404-975-4839 (international) en utilisant le code d'accès 371859. Un lien de préinscription est disponible et une retransmission audio sera accessible dans la section Investisseurs du site web d'Iterum après la conférence.
Iterum Therapeutics (Nasdaq: ITRM), ein Pharmaunternehmen, das sich auf orale und intravenöse Antibiotika der nächsten Generation gegen multiresistente Erreger spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 13. Mai 2025 geplant, und zwar vor Öffnung der US-Märkte. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, um die Finanzergebnisse zu besprechen und ein Geschäftsupdate zu geben.
Investoren können die Telefonkonferenz unter der Nummer 833-470-1428 (national) oder 404-975-4839 (international) mit dem Zugangscode 371859 verfolgen. Ein Voranmeldelink ist verfügbar, und nach der Telefonkonferenz wird ein Audiowebcast im Bereich Investoren auf der Website von Iterum abrufbar sein.
- None.
- None.
DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access Code 371859. To pre-register for this call, please go to the following link: https://events.q4inc.com/attendee/655264003. The audio webcast can be accessed under “Financials & Filings” in the Investors section of the Company’s website at www.iterumtx.com following the call.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its new drug application for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When will ITRM release its Q1 2025 earnings report?
What time is Iterum Therapeutics' Q1 2025 earnings call?
How can investors access ITRM's Q1 2025 earnings call?
What is Iterum Therapeutics' main business focus?
